GENE ONLINE|News &
Opinion
Blog

2020-04-11| Asia-PacificCOVID-19

Chugai Initiates Actemra’s Phase 3 COVID-19 Trials in Japan

by GeneOnline
Share To

Recently, the USFDA approved phase 3 trials to evaluate the repurposed rheumatoid arthritis drug, Actemra in treating adult patients with severe COVID-19 pneumonia. Roche’s strategic partner, Chugai now follows suit in Japan.

Actemra is a recombinant, humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. It is the world’s first anti-IL-6 receptor antibody created in Japan and is originally prescribed for patients suffering from rheumatoid arthritis, Takayasu arteritis, and giant cell arteritis. Several studies and clinical reports have indicated that an over-activation of the immune response could be a major factor responsible for COVID-19 severity in patients. This phenomenon, known as the cytokine storm, is characterized by the increase of cytokines such as IL-2, IL-6, IL-10, etc. Besides, an elevated level of IL-6 has been associated with the need for mechanical ventilation. Due to this reason, Actemra is chosen as one of the potential candidates against the SARS-CoV-2 virus and is anticipated to benefit victims.

On March 23rd, Genentech, a member of the Roche group was approved by the FDA to conduct a double-blind, placebo-controlled Phase 3 clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) to evaluate the drug safety and efficacy of Actemra in patients with severe COVID-19 pneumonia. Now Japanese drug manufacturer, Chugai Pharmaceutical Co Ltd., a strategic partner of Roche has also announced plans to initiate phase 3 trials for Actemra in Japan. Chugai has filed a clinical trial notification with the Pharmaceuticals and Medical Devices Agency.

Scientists around the globe are confronting the COVID-19 challenge through multiple approaches. That includes the development and manufacture of COVID-19 detection kits, antibodies, vaccine candidates, convalescent plasma therapy and antivirals like remdesivir, kaletra (lopinavir/ritonavir) and favipiravir among others. Along the same lines, many repurposed drugs like Actemra, anti-malarial drug hydroxychloroquine, Asthma drug Alvesco, and anti-parasitic drug Ivermectin have shown early promise. Multiple clinical trials are currently ongoing around the world to test the efficacy of these candidates in treating COVID-19 patients. It remains to be seen, how many of them will turn out to be fruitful.

Related Article: Amgen, Adaptive Biotechnologies Collaborate to Strengthen COVID-19 Fight

References
  1. https://www.chugai-pharm.co.jp/english/news/detail/20200324093000_711.html
  2. https://www.chugai-pharm.co.jp/news/detail/20200408170000_969.html
  3. https://www.medrxiv.org/content/10.1101/2020.04.01.20047381v1
  4. https://www.medrxiv.org/content/10.1101/2020.03.30.20048058v1

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
R&D
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
R&D
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
STLI Webinar Series 1: Experts Discuss Regulatory Trends in Regenerative Medicine
2024-07-16
LATEST
Eli Lilly’s Tirzepatide Gets Approval in China for Weight Loss Management
2024-07-22
Roche Reports Positive Clinical Trial Results for Two Diabetes-Related Eye Disease Therapies
2024-07-19
7th Person in History Possibly Cured From HIV After Stem Cell Transplant for Acute Myeloid Leukemia
2024-07-19
Large RCT Finds Time-Lapse Imaging for Embryo Selection in IVF Does Not Improve Live Birth Rates
2024-07-19
Assessment of Supply Chain Risk Key to Improving Medicine Access
2024-07-18
SK Biopharma and Full-Life Sign US$571.5 Million Deal for Innovative Radiopharmaceutical FL-091
2024-07-18
Autoimmune Patients See Breakthrough Response to Allogeneic CD19-Targeted CAR-T Therapy
2024-07-18
EVENT
Scroll to Top